-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAL-02 in Community-Acquired Bacterial Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAL-02 in Community-Acquired Bacterial Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAL-02 in Community-Acquired Bacterial Pneumonia Drug Details: CAL-02 (combioxin) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Non-Small Cell Lung Cancer Drug...
-
Innovation Ranking
Innovation Ranking – Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals Inc (Eagle) is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s key commercial products encompass pharmaceutical injectables, including Ryanodex for exertional heatstroke; Bendeka, and Belrapzo, both for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pipeline products of the company include EP-4104 (dantrolene sodium) for exertional heat stroke (EHS) and nerve agent exposure; EA-114 (fulvestrant) for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)...
-
Product Insights
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024
Empower your strategies with our Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Methicillin-resistant Staphylococcus aureus (MRSA) infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections; others are hospital-aquired (HA-MRSA). Risk factors for MRSA infection are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin...
-
Product Insights
NewCommunity Acquired Pneumonia – Drugs In Development, 2024
Empower your strategies with our Community Acquired Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Community Acquired Pneumonia drugs in development market research...
-
Product Insights
NewHepatitis C – Drugs In Development, 2024
Empower your strategies with our Hepatitis C – Drugs In Development, 2024 report and make more profitable business decisions. Hepatitis C is a contagious viral infection affecting the liver. It spreads on contact with infected blood. It may be a mild condition or may be chronic, leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The offspring of...
-
Product Insights
NewPost Operative Nausea And Vomiting – Drugs In Development, 2024
Empower your strategies with our Post Operative Nausea And Vomiting – Drugs In Development, 2024 report and make more profitable business decisions. Post Operative Nausea and Vomiting is one of the most common problems observed after chemo, anesthesia, and surgical interventions. Triggering of CTZ, vagal mucosal pathway, Neuronal pathways etc. when stimulated activates the sensation of vomiting. Nausea is defined as an unpleasant sensation while nausea is a forceful expulsion of even a small amount of upper gastrointestinal contents. Surgical factors,...
-
Product Insights
NewCommunity-Acquired Bacterial Pneumonia – Drugs In Development, 2024
Empower your strategies with our Community-Acquired Bacterial Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Community-acquired pneumonia is defined as pneumonia that is acquired outside the hospital. The most commonly identified pathogens are Streptococcus pneumoniae, Haemophilus influenzae, atypical bacteria (ie, Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella species), and viruses. Symptoms and signs are fever, cough, sputum production, pleuritic chest pain, dyspnea, tachypnea, and tachycardia The Community-Acquired Bacterial Pneumonia drugs in development market research report provide comprehensive information...
-
Product Insights
NewEnd-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Drugs In Development, 2024
Empower your strategies with our End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Drugs In Development, 2024 report and make more profitable business decisions. End-stage kidney disease, also called end-stage renal disease (ESRD), refers to complete or almost complete kidney failure. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion, and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis, and certain autoimmune conditions, such as lupus. Treatment includes...